Login to Your Account

Other News To Note

Thursday, February 14, 2013
Algeta ASA, of Oslo, Norway, said that its partner Bayer AG, of Leverkusen, Germany, has received notification that the New Drug Application (NDA) for the investigational compound Radium Ra 223 Dichloride (radium-223) has been accepted for filing and granted priority review by the FDA.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription